Liquidia's (LQDA) "Buy" Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Liquidia (NASDAQ:LQDA - Free Report) in a research note published on Thursday,Benzinga reports. Needham & Company LLC currently has a $19.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. Lifesci Capital began coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an "outperform" rating and a $30.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $29.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Scotiabank assumed coverage on Liquidia in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $30.00 target price for the company. Finally, Wells Fargo & Company began coverage on shares of Liquidia in a report on Friday, December 20th. They issued an "overweight" rating and a $20.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $25.38.

Liquidia Price Performance

Shares of LQDA traded up $0.06 during trading hours on Thursday, hitting $12.46. The company's stock had a trading volume of 607,383 shares, compared to its average volume of 776,677. The business has a 50 day simple moving average of $11.10 and a two-hundred day simple moving average of $11.03. Liquidia has a 52-week low of $8.26 and a 52-week high of $16.99. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -7.64 and a beta of 0.23.

Insiders Place Their Bets

In other Liquidia news, insider Rajeev Saggar sold 2,526 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $11.19, for a total transaction of $28,265.94. Following the transaction, the insider now directly owns 204,857 shares in the company, valued at $2,292,349.83. This trade represents a 1.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Roger Jeffs sold 8,053 shares of the business's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $89,468.83. Following the completion of the sale, the chief executive officer now owns 812,193 shares of the company's stock, valued at approximately $9,023,464.23. The trade was a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,007 shares of company stock valued at $245,780 in the last quarter. Corporate insiders own 30.10% of the company's stock.

Institutional Trading of Liquidia

Institutional investors have recently added to or reduced their stakes in the business. Whitefort Capital Management LP boosted its holdings in Liquidia by 119.8% during the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company's stock valued at $17,020,000 after acquiring an additional 927,546 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock worth $3,903,000 after buying an additional 230,820 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Liquidia by 855.3% in the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock worth $2,354,000 after buying an additional 210,753 shares during the period. Anson Funds Management LP purchased a new stake in Liquidia during the 3rd quarter valued at $1,764,000. Finally, Sapient Capital LLC bought a new stake in Liquidia in the 3rd quarter worth $1,336,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).